

Content highlights

Publication date
July 2026

Updated throughout the year to reflect the latest major-market events

Geography
United States, EU5, Japan

Primary research
Country-specific interviews with thought-leading medical oncologists

Survey data collected for this and other Clarivate research

Epidemiology
Diagnosed incidence of ovarian cancer by country; clinically and market-relevant drug-treatable populations

Forecast
10-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2035, segmented by brands / generics and epidemiological subpopulations

Drug treatments
Coverage of key current and late-phase emerging therapies

Ovarian Cancer

Disease Landscape & Forecast

The therapeutic landscape for ovarian cancer is undergoing rapid and meaningful transformation, fueled by continued progress in targeted therapies, including antibody-drug conjugates (ADCs) and innovative immuno-oncology approaches. Anti-angiogenic agents and PARP inhibitors remain central pillars of treatment, supported by robust evidence demonstrating their value as maintenance and targeted options for selected patients, particularly those with *BRCA* mutations or homologous recombination deficiency (HRD). A major recent advancement has been the introduction of mirvetuximab soravtansine, the first folate receptor-alpha (FR α)-directed ADC, which has redefined management for patients with FR α -high (TPS \geq 75%), platinum-resistant disease and highlighted the therapeutic potential of biomarker-driven ADCs. In addition, the late-stage pipeline is expanding at unprecedented pace with next-generation ADCs, emerging immune checkpoint combinations, and agents targeting novel molecular pathways, collectively poised to diversify treatment options and further personalize care.

Questions answered

- What are the estimated sizes of clinically and commercially relevant drug-treatable ovarian cancer populations, and how will drug-treatment rates change (if at all) over time?
- How will the ovarian cancer market evolve over the 10-year forecast period? What are the main drivers and constraints?
- What are interviewed experts' opinions on current therapies for ovarian cancer?
- How will the adoption and anticipated label expansions of antibody-drug conjugates, such as mirvetuximab soravtansine, reshape the ovarian cancer treatment landscape?
- What is the clinical and commercial potential of emerging therapies, such as relacorilant or raludotatug deruxtecan?

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.

Learn more about Clarivate's full suite of ovarian cancer solutions:

lsh.support@clarivate.com | clarivate.com